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The present study describes the development and validation of a dissolution method for carvedilol 
compression-coated tablets. Dissolution test was performed using a TDT-06T dissolution apparatus. Based 
on the physiological conditions of the body, 0.1N hydrochloric acid was used as dissolution medium 
and release was monitored for 2 hours to verify the immediate release pattern of the drug in acidic pH, 
followed by pH 6.8 in citric-phosphate buffer for 22 hours, to simulate a sustained release pattern in the 
intestine. Influences of rotation speed and surfactant concentration in medium were evaluated. Samples 
were analysed by validated UV visible spectrophotometric method at 286 nm. 1% sodium lauryl sulphate 
(SLS) was found to be optimum for improving carvedilol solubility in pH 6.8 citric-phosphate buffer. 
Analysis of variance showed no significant difference between the results obtained at 50 and 100 rpm. 
The discriminating dissolution method was successfully developed for carvedilol compression-coated 
tablets. The conditions that allowed dissolution determination were USP type I apparatus at 100 rpm, 
containing 1000 ml of 0.1N HCl for 2 hours, followed by pH 6.8 citric-phosphate buffer with 1% SLS 
for 22 hours at 37.0 ± 0.5 ºC. Samples were analysed by UV spectrophotometric method and validated 
as per ICH guidelines. 
Uniterms: Carvedilol/coated tablets. Compression coated tablets/dissolution. pH 6.8 citric-phosphate 
buffer. Hydrochloric acid. Sodium lauryl sulphate.
O presente estudo descreve o desenvolvimento e a validação de método de dissolução para comprimidos 
revestidos de carvedilol. O teste de dissolução foi efetuado utilizando-se o aparelho para dissolução 
TDT‑06T. Com base nas condições fisiológicas do organismo, utilizou‑se ácido clorídrico 0,1 N como 
meio de dissolução e a liberação foi monitorada por 2 horas para se verificar o padrão de liberação imediata 
do fármaco em condições de pH baixo, seguidas por pH 6,8 em tampão cítrico‑fosfato por 22 horas, para 
simular o padrão de liberação controlada no intestino. Avaliou‑se a influência da velocidade de rotação 
e a concentração de tensoativo no meio. As amostras foram analisadas por método espectrofotométrico 
UV‑visível validado, em 286 nm. O laurilsulfato sódico a 1% (SLS) mostrou-se ótimo para aumentar 
a solubilidade do carvedilol em pH 6,8 em tampão cítrico‑fosfato. A análise da variância não mostrou 
diferença significativa entre os resultados obtidos a 50 e a 100 rpm. O método da dissolução discriminante 
foi desenvolvido com sucesso para os comprimidos revestidos de carvedilol. As condições que permitiram 
a determinação da dissolução foram: aparelho USP tipo I a 100 rpm, contendo 1000 mL de HCL 0,1 N 
por 2 horas, seguido de pH 6,8 com tampão cítrico‑fosfato, com 1% de SLS por 22 horas a 37,0 ± 0,5 oC. 
Amostras foram analisadas por método espectrofotométrico e validadas pelas normas ICH.
Unitermos: Carvedilol/comprimidos revestidos. Comprimidos revestidos por compressão/dissolução. 
Tampão cítrico‑fosfato pH 6.8. Ácido clorídrico. Laurilsulfato de sódio. 
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INTRODUCTION
Dissolution testing has been proven to be important 
tool for evaluating the performance of solid dosage forms 
(Dressman et al., 1998). Developing an appropriate in 
vitro dissolution test for drug products with limited water 
solubility has been a challenge for scientists. Lipophilic 
drugs are classified into classes II or IV by the Biophar-
maceutical Classification System (BCS), depending on 
their apparent permeability (Papp values). Drug release is 
usually the rate-limiting step for oral absorption of these 
substances (Lobenberg et al., 2000; Soni et al., 2008).
An ideal dissolution test should provide product 
quality information as well as some preliminary in vivo/in 
vitro correlation (IVIVC) or biorelevance (Emani, 2006). 
For insoluble compounds, surfactants may be employed, 
such as sodium lauryl sulfate (SLS) or polysorbate 80 (e.g. 
Tween® 80), to assist in drug dissolution and solubilisa-
tion (Balakrishnan et al., 2004). Usually, biorelevant dis-
solution testing is performed separately using media such 
as simulated gastric fluid (SGF), simulated intestinal fluid 
(SIF), milk and fasted-state or fed-state simulated intes-
tinal fluid (FaSSIF or FeSSIF) (Nicolaides et al.,1999).
Dissolution testing is used to guide the development 
of new drug products and to assess the lot-to-lot variabil-
ity of drug products. Analytical methods are validated to 
ensure that they are suitable for their intended use and pro-
vide accurate and reliable data. Validation of a dissolution 
method typically involves validation of the end analysis 
method (Galia et al., 1998; ICH, 2005).
The present study describes the development and 
validation of a dissolution method for compression-
coated tablets with quick and slow release characteristics. 
Carvedilol, or (±)-1-9H‑(carbazol‑4‑yloxy)‑3‑[[2‑(2‑
methoxyphenoxy)ethyl]amino]‑2‑propanol (Figure 1), 
is an antihypertensive agent with β and α1-adrenergic 
receptor-blocking activities (Ruffolo et al., 1990; Nichols 
et al., 1991; De et al., 1994).
Carvedilol has a greater antioxidant activity than 
other commonly‑used β blockers (Nakamura et al., 2002; 
Kukin et al., 1999). It is widely prescribed for the treat-
ment of essential hypertension, angina pectoris (Packer 
et al., 2002; Ruffolo et al., 1992) and congestive heart 
failure (Poole-wilson et al., 2002). Its biological half-life 
is 6 to 10 hours and its usual dose is 3.125, 6.25, 12.5 and 
25mg, two to three times a day. Short biological half-life 
and high frequency of administration make carvedilol 
a suitable candidate for administration by a quick/slow 
delivery system. Conventional controlled dosage forms 
delay the release of the drug but do not provide a rapid 
onset of action. This can be overcome by quick/slow re-
lease pattern of compression-coated tablets. The present 
study describes the process of selection, development and 
validation of a dissolution method for 25 mg carvedilol 
compression-coated tablets. A dissolution method for 
carvedilol compression coated tablets had not been re-
ported in the literature.
MATERIAL AND METHODS
Material
Carvedilol BP was received as a gift sample from 
Unichem India Laboratories. All chemicals and solvents 
used were of analytical reagent grade. Hydroxy propyl 
methyl cellulose (HPMC)K4M (Colorcon India), polyox 
WSR 205 (Dow chemical’s), microcrystalline cellulose, 
magnesium stearate, talc, sodium starch glycollate, starch, 
disodium hydrogen ortho phosphate, citric acid, hydro-
chloric acid, sodium lauryl sulfate (SLS) (Sd fine chem 
pvt. Ltd, Mumbai) were used.
Instrumentation
Equipment and instruments used in the present study 
included: electronic balance (Reputed Micro System), 
tablet compression machine (Rimek mini press- I), hard-
ness tester (Monsanto), Roche friabilator, UV Spectropho-
tometer (UV-1800 Shimadzu), Dissolution test apparatus 
TDT-06T (Electrolab, Mumbai, India) and laboratory 
stirrer (Remi Instruments division).
Methodology
Solubility of drug in different dissolution media
The selection of a dissolution medium may be 
based on the solubility data and dosage range of the drug 
product. The saturation solubility of carvedilol was deter-
mined in distilled water, hydrochloric acid solution (pH 
1.2), citric-phosphate buffer (pH 4.5, 6.8, 7.4) and pH 6.8 
citric-phosphate buffer with sodium lauryl sulphate (0.1%, 
0.5%, and 1.0%). Fifty miligrams of carvedilol were accu-
rately weighed and added to 15 ml of the afforementioned 
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FIGURE 1 - Chemical structure of carvedilol.
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dissolution medium in a 25 ml volumetric flask and then 
agitated continuously at room temperature for 24 hours 
using a mechanical shaker. The solutions were kept aside 
for 24 hours for equilibrium, at the same temperature. Af-
ter equilibrium, solutions were filtered through Whatman 
fiters (0.45 micron); filtrates were suitably diluted and 
analysed by UV spectrophotometer at 286 nm. Solubility 
of drug in each medium was determined in triplicate.
Dissolution test conditions
The dissolution method was developed using a 
TDT-06T dissolution apparatus. Volume of dissolution 
medium was selected based on the solubility data. Influ-
ences of rotation speed and surfactant concentration in 
pH 6.8 citric-phosphate buffer were evaluated. At 30, 
45, 60 minutes time interval, 10 ml sample aliquots were 
withdrawn and replaced with an equal volume of fresh 
medium to maintain a constant total volume. Aliquots were 
passed through a filter and analysed using the previously 
validated UV spectrophotometric method at 286 nm, with 
dissolution medium in reference cell.
Discrimination power of selected dissolution method
Discriminatory dissolution profiles are highly de-
sirable for differentiating between products having dif-
ferences in pharmaceutical attributes (formulation and/
or manufacturing process differences) that may reflect 
corresponding differences in vivo.
Two formulations were prepared which differed in 
concentration of HPMC and MCC in core tablets, in order 
to challenge the discrimination power for the dissolution 
method (Table I). The core tablets were prepared by direct 
compression method, where the desired amount of blend 
(equivalent to 50 mg tablet weight) was compressed into 
tablets using a rotary tablet-compression machine equipped 
with a 5.5 mm concave punch. The immediate release layer 
(coat layer) was composed of drug (5 mg), starch, sodium 
starch glycollate, microcrystalline cellulose, magnesium 
stearate and talc, for both formulations. To prepare the 
compression-coated tablets, half the amount of immediate 
release powder blend was put into the die cavity with 8 mm 
diameter to make a powder bed, on the center of which a 
core tablet was placed. Once more, half the amount of pow-
der was added to cover the core tablet, and the layers were 
compressed at a compression force of 5 kN.
Dissolution profiles of batch F1 and F2 were com-
pared using a similarity factor (f2) and dissimilarity factor 
(f1). Values for f1 and f2 were calculated using equations 
1 and 2, respectively. The f2 factor measures the close-
ness between the two profiles and f1 measures difference 
between the two profiles:
 (1)
 (2) 
where Rt and Tt are the percentage of drug dissolved 
at each time point for the test and reference products, 
respectively. A value of f1 over 15 indicates significant 
dissimilarity and a value of f2 over 50 indicates significant 
similarity in results (Gupta et al., 2010).
Method validation
UV/VIS spectrophotometry and high performance 
liquid chromatography are analytical methods widely 
used for quantifying drug release in dissolution tests 
(Wang et al., 2006). In the present research work, the UV 
spectrophotometric method was used to analyse carvedilol 
released in the dissolution medium. It was validated as per 
ICH guideline (ICH, 2005).
RESULTS AND DISCUSSION
Solubility of drug in different media
Saturation solubility and relative sink conditions 
of carvedilol in different dissolution medium are shown 
TABLE I - Composition of two batches of core tablets of carvedilol compression-coated tablets to challenge the discriminating 
power of the dissolution 
Batch no. Weight of drug 
(mg)
Weight of PEO 
WSR 205 ( mg)
Weight of HPMC 
K4M (mg)
Weight of MCC 
(mg)
Weight of 
magnesium 
stearate (mg)
Weight of talc 
(mg)
F1 20 5 5 18 1 1
F2 20 5 10 13 1 1
PEO, HPMC and MCC stand for polyethylene oxide, hydroxypropyl methyl cellulose and microcrystalline cellulose, respectively.
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in Table II. Carvedilol showed good solubility in acidic 
medium (0.1 N HCl) and solubility decreased at higher 
pH values. For poorly soluble drugs, surfactants can be 
used to enhance drug solubility (Wang et al., 2006). The 
FDA recommended the use of SLS in dissolution media 
for many lipophilic drugs. Using 3% of SLS has been sug-
gested for conducting dissolution tests for insoluble drugs, 
such as acetracin and orlistate (Amit et al., 2010). The ratio 
of solubility to drug concentration, expressed as CS/CD (S 
value), represents the closeness to the sink conditions, with 
values greater than 3 considered as sink according to USP 
(Jamzad et al., 2006). In the present study, 1.0 % w/v SLS 
in pH 6.8 citric-phosphate buffer medium provided sink 
conditions, hence 1.0% SLS was chosen to enhance the 
solubility of the drug in 6.8 citric-phosphate buffer.
Development of dissolution test conditions
Retention times of formulations in the stomach 
depend on the dosage size and on whether or not the 
formulation is taken with a meal. To develop dissolution 
tests on the basis of gastrointestinal physiology, mean 
residence times in various segments of the gastrointes-
tinal tract are considered (Klein et al., 2005). Patients 
are advised to take carvedilol after eating a meal (White 
et al., 2007). Postprandial mean residence time of pellet 
and non-disintegrating tablet in the stomach ranges from 
2-4 hours (Klein et al., 2005); hence 0.1N HCl was used 
as dissolution medium for 2 hours, to check the immedi-
ate release pattern of the drug in acidic pH. A value of S 
greater than 3 (Table II) at 0.1 N HCl eliminates the need 
for surfactants in the dissolution medium. After 2 hours, 
a pH 6.8 citric-phosphate buffer with 1% SLS was chosen 
to study the dissolution of compression-coated tablets for 
22 hours, in order to simulate the slow release pattern in 
the small and large intestines.
The influence of the rotation speed was evaluated 
and the analysis of variance showed no significant dif-
ference between the results obtained at 50 and 100 rpm 
(p<0.05). The drug release percentage in pH 6.8 citric-
phosphate buffer medium at 100 rpm was slightly higher 
than the release at 50 rpm (Table III).
A Basket apparatus was selected for dissolution 
of compression-coated carvedilol tablets as it allowed 
for easy change of the dissolution medium after 2 hours, 
without disturbing the dosage form. The volume of the 
dissolution medium was selected as 1000 mL, based on 
the solubility data.
TABLE II - Saturation solubility and relative sink conditions of carvedilol in different dissolution media (n=3)
Dissolution medium Solubility (µg/mL) S value = Cs/Cd (25 mg tablet)
Water 0.98 ± 0.12 0.040
0.1 N HCl 89.2 ± 0.03 3.568
pH 4.5 citric-phosphate buffer 44.2 ± 0.012 1.768
pH 6.8 citric-phosphate buffer 15.7 ± 0.05 0.063
pH 7.4 citric-phosphate buffer 10.6 ± 0.01 0.424
pH 6.8 citric-phosphate buffer + 0.1 % SLS 29.4 ± 0.03 1.176
pH 6.8 citric-phosphate buffer + 0.5% SLS 54.2 ± 0.02 2.168
pH 6.8 citric-phosphate buffer + 1% SLS 79.8 ± 0.13 3.192
CS stands for saturation solubility of carvedilol; Cd stands for concentration of carvedilol after complete dissolution; SLS stands 
for sodium lauryl sulfate.
TABLE III - In vitro drug release of carvedilol compression-
coated tablet
Sr. No. Time (hours) % Drug 
release
Immediate layer of tablet (5 mg)
1 0 0
2 1 80.75
3 2 100.8
Sustained layer of tablet (20 mg)
4 3 21.29
5 4 23.92
6 6 28.62
7 8 34.81
8 10 40.79
9 12 47.45
10 16 65.76
11 20 84.28
12 24 97.97
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Based on these results and on requirements of dos-
age form, the optimised conditions for the dissolution 
test of compression-coated carvedilol tablets were a USP 
apparatus I containing 1000 ml of 0.1N HCl for the first 2 
hours, followed by a pH 6.8 citric-phosphate buffer with 
1% of SLS for 22 hours with a stirring speed of 100 rpm. 
Under these conditions, the optimised batch of carvedilol 
compression-coated tablets showed a drug release of 
100.8% from the immediate layer in the first 2 hours and 
a drug release of 97.97% from the sustained release layer 
after 22 hours (Table III, Figure 2). The drug was stable 
for 24 hours in the dissolution medium (variation less than 
2%). Acceptance criteria are derived in the form of “Q 
factors”, a minimum amount dissolved at a given time as 
a percentage of the labeled content. Acceptance criteria, 
Q, for the compression-coated tablets were in the range 
of 75% to 80%.
Discrimination power of selected dissolution 
method
Results of the dissolution study for both formula-
tions, F1 and F2, are given in Table IV. Comparison of the 
dissolution profile for batches F1 and F2 was conducted 
by Model-Independent analysis, using the values of f1 
and f2 to confirm the discriminating power of the dis-
solution method. The optimised dissolution conditions 
in this study enabled differentiation between the two 
formulations, having varying concentrations of HPMC 
and MCC, with f1 and f2 values of 17.65 and 41.46, 
respectively. Student’s t‑test was used to find maximum 
significant difference in the dissolution profile to repre-
sent discrimination power. The p value was found to be 
0.4657 for formulations F1 and F2, indicating maximum 
significant difference in the in vitro drug release profile 
for both batches.
FIGURE 2 - In vitro drug release profile of carvedilol 
compression-coated tablet in 0.1 N HCl for 2 hours and in pH 
6.8 citric‑phosphate buffer for the next 22 hours at 100 rpm.
TABLE IV - Comparison of in vitro drug release profile of two 
batches of carvedilol compression-coated tablets to challenge 
discriminating power
Time (hours) % drug release
Batch F1 Batch F2
0 0 0
1 17.23 15.69
2 21.71 23.54
3 35.02 26.09
4 41.3 30.42
6 57.93 35.79
8 66.5 45.92
10 77.55 56.44
12 85.62 62.91
16 100.51 77.58
20 100.18 101.02
24 99.37 103.46
Method validation
Specificity
The UV spectrophotometric method may be used if 
the drug has a UV chromophore and no UV interferences, 
due to excipients used in the formulation being observed 
(Fortunato, 2005). Specificity was examined by analysing 
a placebo solution, which consisted of all the excipients 
without the drug. The absorption spectrum of the drug 
in dissolution medium showed an absorbance peak at 
286 nm. At this wavelength, no interference of excipients 
was observed (Figure 3).
Linearity
Linearity of the method was evaluated with a six‑
point calibration curve, spanning a concentration range 
of 5‑30 μg/mL of drug substance in 0.1 N HCl and in 6.8 
citric-phosphate buffer with 1% SLS. Three independent 
determinations were performed for each concentration. 
Linearity curves were plotted for media, 0.1 N HCl 
(Figure 4) and 6.8 citric-phosphate buffer with 1% SLS 
(Figure 5), considering mean absorbance and standard 
deviation (SD) for each concentration. These data indi-
cated that the absorbance was linear over the concentration 
range of 5‑30 μg/mL of drug substance. The correlation 
coefficient (R2) value for the regression line was 0.999, 
with a slope of 0.136 and y-intercept of 0.049 in 0.1 N 
HCl. The R2 value for the regression line was found to be 
0.999 in 6.8 citric-phosphate buffer with 1% SLS, with a 
slope of 0.134 and y-intercept of 0.049. These results were 
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considered acceptable and the linearity curves were used 
to calculate in vitro drug release studies.
Range
The specified range is normally derived from linear-
ity studies and depends on the intended application of the 
procedure. As per ICH guideline, if the specifications for 
a controlled released product cover a region from 20% 
after 1 hour, up to 90% after 24 hours, the validated range 
would be 0-110% of the label claim. In the present study, 
100% drug was released from the immediate release layer 
in up to 2 hours, 21.29% drug was released at 3 hours from 
FIGURE 3 – UV spectra of drug and placebo.
FIGURE 4 - Linearity curve of carvedilol in 0.1 N HCL.
FIGURE 5 - Linearity curve of carvedilol in 6.8 citric-phosphate 
buffer with 1 % SLS.
the sustained release layer and 99.99% drug was released 
after 24 hours, so the validated range would be 0-110% 
of the label claim.
Precision
Precision of the method was determined by measur-
ing the repeatability, intraday precision and interday preci-
sion. The repeatability study (n = 6) carried out showed 
a maximum percentage relative SD of 0.72% among 
samples prepared on the same day under the same condi-
tions. At interday and intraday, the maximum percentages 
of relative SD were found to be 1.32 and 0.97, respectively.
The method also showed intermediate precision 
with maximum difference in RSD percentage of 0.26%, 
among the results of six analytical solutions prepared by 
two different analysts on different days (n=3).
Accuracy
The accuracy was demonstrated by the recovery of 
known amounts of carvedilol in the dissolution vessels. 
In the present study, four concentrations were evaluated 
(15, 20, 25 and 30 μg/mL) and each concentration was 
measured three times. The recovery percentage found 
ranged from 99.26 to 101.40, which indicates the accuracy 
of the method. The recovery percentage was calculated in 
triplicate and the mean value was considered.
Solution stability
Solution stability was determined by measuring 
absorbance of 15μg/ml of carvedilol solution under the 
dissolution test conditions for up to 30 hours. All of the as-
say results during this period of time were within 98–102% 
of the initial value.
CONCLUSION
The discriminating dissolution method was success-
fully developed for carvedilol compression-coated tablets. 
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The conditions that allowed the dissolution determination 
were USP type I apparatus at 100 rpm, containing 1000 mL 
of 0.1 N HCl for first 2 hours and pH 6.8 citric‑phosphate 
buffer with 1% SLS for the next 22 hours at 37.0 ± 0.5 ºC. 
Carvedilol stability was ensured under the developed 
dissolution conditions. Samples were analysed using the 
validated UV spectrophotometric method.
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